CoChat
Sign Up
Cited by 52

Risk of hypertension amongst Swedish male snuff users: a prospective study

Hergens, M.‐P., Lambe, M., Pershagen, G., Ye, W.·2008·Journal of Internal Medicine
DOI 10.1111/j.1365-2796.2008.01939.x
Open this paper in CoChat — free account

Abstract

Abstract.: Background. The scientific evidence on whether long‐term use of snuff is associated with high blood pressure is limited, inconsistent and based only on cross‐sectional data. Objective. We aimed at studying the risk of hypertension in relation to long‐term use of snuff based on longitudinal data. Design. Repeated health check‐ups were offered to all employees in the Swedish construction industry between 1978 and 1993. Blood pressure was measured at the health check‐up and information on tobacco use and other risk factors was collected through questionnaires. Setting. In total, 120 930 never smoking men with information on blood pressure and snuff use at baseline were included. The association of high blood pressure and snuff use at baseline was estimated by logistic regression. Further, 42 055 men were identified as normotensive at baseline and had at least one subsequent health check‐up. Through repeated blood pressure measurements and linkage to the Swedish National Inpatient Register, information on hypertension was obtained. Relative risk estimates were derived from Cox proportional hazards regression model. Results. Almost 30% of all men had used snuff. The adjusted odds ratio of high blood pressure amongst snuff users at baseline was 1.23 (95% CI 1.15–1.33) compared to never snuff users. The relative risk of high blood pressure during follow‐up was 1.39 (95% CI 1.08–1.79) amongst snuff users and 1.36 (95% CI 1.07–1.72) for hypertension as recorded in the Inpatient Register. Conclusion. Use of Swedish moist snuff appears to be associated with a moderately increased risk of hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2008.01939.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Snus users compared to never-users have increased odds of high blood pressure at baseline (aOR = 1.23; 95% CI: 1.15-1.33), during follow-up (aOR = 1.39; 95% CI: 1.08-1.79), and of hypertension (aOR = 1.36; 95% CI: 1.07-1.72).

    “increased odds of high blood pressure at baseline (adjusted odds ratio (aOR) = 1.23; 95% CI: 1.15-1.33)and during follow-up (aOR = 1.39; 95% CI: 1.08-1.79),as well as increased odds of hypertension (aOR = 1.36; 95% CI: 1.07-1.72)among snus users compared to never-users (Hergens et al. 2008).”

    From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Hergens et al. 2008

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. Arredondo J, Nguyen VA, Chernyavsky I et al. A receptor-med- iated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest 2001; 81: 1653-68.
  2. Henley SJ, Connell CJ, Richter P et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007; 16: 22-8.
  3. Huhtasaari F, Lundberg V, Eliasson M et al. Smokeless tobacco as a possible risk factor for myocardial infarction: a population- based study in middle-aged men. J Am Coll Cardiol 1999; 34: 1784-90.
  4. Huhtasaari F, Asplund K, Lundberg V et al. Tobacco and myo- cardial infarction: is snuff less dangerous than cigarettes? BMJ 1992; 305: 1252-6.
  5. Hergens MP, Alfredsson PL, Bolinder G et al. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007; 262: 351-9.
  6. Hergens MP, Ahlbom A, Andersson T et al. Swedish moist snuff and myocardial infarction among men. Epidemiology 2005; 16: 12-6.
  7. Henley SJ, Thun MJ, Connell C et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005; 16: 347- 58.
  8. Bolinder G. Long-term use of smokeless tobacco. Cardiovascu- lar mortality and risk factors. Thesis. Stockholm: Department of Medicine, Karolinska Institutet, 1997.
  9. Fant RV, Henningfield JE, Nelson RA et al. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 1999; 8: 387-92.
  10. Benowitz NL, Porchet H, Sheiner L et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: compari- son with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23-8.
  11. Squires WG Jr, Brandon TA, Zinkgraf S et al. Hemodynamic effects of oral smokeless tobacco in dogs and young adults. Prev Med 1984; 13: 195-206.
  12. Ernster VL, Grady DG, Greene JC et al. Smokeless tobacco use and health effects among baseball players. JAMA 1990; 264: 218-24.
  13. Westman EC. Does smokeless tobacco cause hypertension? South Med J 1995; 88: 716-20.
  14. Wolk R, Shamsuzzaman AS, Svatikova A et al. Hemodynamic and autonomic effects of smokeless tobacco in healthy young men. J Am Coll Cardiol 2005; 45: 910-4.
  15. Bolinder G, Noren A, Wahren J et al. Long-term use of smoke- less tobacco and physical performance in middle-aged men. Eur J Clin Invest 1997; 27: 427-33.
  16. Hirsch JM, Hedner J, Wernstedt L et al. Hemodynamic effects of the use of oral snuff. Clin Pharmacol Ther 1992; 52: 394-401.
  17. Bolinder GM, Ahlborg BO, Lindell JH et al. Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey. J Intern Med 1992; 232: 327-34.
  18. Bolinder G, de Faire U. Ambulatory 24-h blood pressure moni- toring in healthy, middle-aged smokeless tobacco users, smok- ers, and nontobacco users. Am J Hypertens 1998; 11: 1153-63.
  19. Siegel D, Benowitz N, Ernster VL et al. Smokeless tobacco, car- diovascular risk factors, and nicotine and cotinine levels in pro- fessional baseball players. Am J Public Health 1992; 82: 417-21.
  20. Eliasson M, Lundblad D, Hagg E et al. Cardiovascular risk fac- tors in young snuff-users and cigarette smokers. J Intern Med 1991; 230: 17-22.
  21. Eliasson M, Asplund K, Evrin PE et al. Relationship of ciga- rette smoking and snuff dipping to plasma fibrinogen, fibrino- lytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995; 113: 41-53.
  22. Wallenfeldt K, Hulthe J, Bokemark L et al. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med 2001; 250: 492-501.
  23. Holm H, Jarvis MJ, Russell MA et al. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology (Berl) 1992; 108: 507-11.
  24. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29: 1422-31. 26 Benowitz NL. Clinical pharmacology of nicotine. Annu Rev Med 1986; 37: 21-32.
  25. Nyren O, Bergstrom R, Nystrom L et al. Smoking and colorec- tal cancer: a 20-year follow-up study of Swedish construction workers. J Natl Cancer Inst 1996; 88: 1302-7.
  26. Furberg H, Lichtenstein P, Pedersen NL et al. Cigarettes and oral snuff use in Sweden: prevalence and transitions. Addiction 2006; 101: 1509-15.
  27. Wigertz A, Westerling R et al. Measures of prevalence: which healthcare registers are applicable? Scand J Public Health 2001; 29: 55-62.
  28. Rothman KJ. Epidemiology An Introduction. New York: Oxford University Press, 2002. Correspondence: Maria-Pia Hergens, Institute of Environmental Medicine, Karolinska Institutet, Box 210, Nobels va ¨g 13, SE 171 77, Stockholm, Sweden. (fax: +46 8 30 45 71; e-mail: maria-pia.hergens@ki.se).

Cited by

Sorted by citations

Authors
Hergens, M. ‐., Lambe, M., Pershagen, G., & Ye, W.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2008-07-10
Volume
264
Issue
2
Pages
187-194
ISSN
  • 0954-6820
  • 1365-2796
DOI
10.1111/j.1365-2796.2008.01939.x
Cited by
52
References
0
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review